A comprehensive view of United Therapeutics Corp.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

United Therapeutics named by Newsweek as one of America’s Most Responsible Companies 2023; selection based on information from corporate social responsibility reports, sustainability reports, public perception of company social responsibility activities

United Therapeutics reports Q3 net income up at US$239.3M from US$162.7M a year ago as revenue grows 16% year-over-year to US$516.0M; net product sales from treprostinil-based products up by $84.4 million in Q3

Court finds Liquidia Technologies’ generic formulation of Tyvaso treprostinil infringes on United Therapeutics’ patent for the drug; ruling could keep Liquidia from marketing the generic until 2027

United Therapeutics reports Q2 net income down at US$116.0M from US$172.6M a year ago, with total revenue up 5% year-over-year to US$466.9M; Q2 sales of treprostinil-based products grew US$42.2M compared to a year ago

Children's Hospital Los Angeles collaborates with United Therapeutics on Phase 4 clinical trial to study rapid infusion of Dinutuximab to treat children with high-risk neuroblastoma, a cancer of the nerve cells; study not yet open for recruiting

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count